Render Target: STATIC
Render Timestamp: 2024-11-14T11:06:15.303Z
Commit: 3c1f305a63297e594ac8d7bb5424007d592d68be
XML generation date: 2024-09-30 01:57:43.557
Product last modified at: 2024-10-23T16:30:10.321Z
1% for the planet logo
PDP - Template Name: Monoclonal Antibody
PDP - Template ID: *******c5e4b77
R Recombinant
Recombinant: Superior lot-to-lot consistency, continuous supply, and animal-free manufacturing.

CD109 (E4I2V) Rabbit mAb #24765

Filter:
  • WB
  • IP
  • IHC

    Supporting Data

    REACTIVITY H M
    SENSITIVITY Endogenous
    MW (kDa) 190
    Source/Isotype Rabbit IgG
    Application Key:
    • WB-Western Blotting 
    • IP-Immunoprecipitation 
    • IHC-Immunohistochemistry 
    Species Cross-Reactivity Key:
    • H-Human 
    • M-Mouse 

    Product Information

    Product Usage Information

    Application Dilution
    Western Blotting 1:1000
    Immunoprecipitation 1:100
    IHC Leica Bond 1:400 - 1:1600
    Immunohistochemistry (Paraffin) 1:200 - 1:800

    Storage

    Supplied in 10 mM sodium HEPES (pH 7.5), 150 mM NaCl, 100 µg/ml BSA, 50% glycerol and less than 0.02% sodium azide. Store at –20°C. Do not aliquot the antibody.

    For a carrier free (BSA and azide free) version of this product see product #34464.

    Protocol

    Specificity / Sensitivity

    CD109 (E4I2V) Rabbit mAb recognizes endogenous levels of total CD109 protein. Species cross-reactivity for IHC-P is human only.

    Species Reactivity:

    Human, Mouse

    Source / Purification

    Monoclonal antibody is produced by immunizing animals with a synthetic peptide corresponding to residues surrounding Val834 of human CD109 protein.

    Background

    CD109 is a glycosylphosphatidylinositol (GPI)-linked glycoprotein that belongs to the alpha2-macroglobulin family of thioester containing proteins (1). CD109 is associated with TGF-beta receptor I (TbRI) and inhibits TGF-beta signaling (2,3). Cleavage of CD109 at its Furin cleavage site results in the release of its large amino-terminal domain, which then binds to the TGF-beta receptor I to inhibit TGF-beta signaling (4-7). CD109 is expressed on a subset of CD34+ bone marrow cells and mesenchymal stem cells, activated platelets, activated T cells, endothelial cells, and a wide variety of tumors (8-10). Elevated CD109 expression has been considered a diagnostic/prognostic marker for several types of cancers (11-14).
    For Research Use Only. Not For Use In Diagnostic Procedures.
    Cell Signaling Technology is a trademark of Cell Signaling Technology, Inc.
    SignalStain is a registered trademark of Cell Signaling Technology, Inc.
    XP is a registered trademark of Cell Signaling Technology, Inc.
    All other trademarks are the property of their respective owners. Visit our Trademark Information page.